Mental Health

Careful selection of pharmacotherapy and close monitoring are crucial to ensuring safety and efficacy.

Pharmacists are key to closing care gaps and supporting long-term recovery.

Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

MM120 shows promise in treating generalized anxiety disorder, demonstrating significant symptom relief and a potential shift in psychiatric treatment approaches.

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.

Research reveals associations between body composition, fitness, and mental health in children, highlighting the impact of obesity on anxiety and depression.

Research shows that individuals who use cannabis to self-medicate, especially those with a history of childhood trauma, face heightened risks of paranoia and adverse mental health outcomes.

Individuals with bipolar disorder are at nearly a 2-fold higher risk of heart failure, which is marked as the main cause of premature cardiovascular mortality.

CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia as an adjunct to antipsychotic treatment.

NRX-100 receives FDA fast track designation, offering hope for treating suicidal ideation in depression and bipolar disorder, addressing a critical health crisis.

Pharmacists guide pregnant women in balancing depression treatment with SSRI safety, addressing risks of untreated depression and neonatal adaptation syndrome.

Joel Stanley of Ajna Biosciences reflects on the regulatory challenges surrounding MDMA-assisted therapy, outlines lessons for future psychedelic drug trials, and emphasizes the importance of scientific rigor, interdisciplinary infrastructure, and the evolving role of pharmacists in ensuring safe clinical integration.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

Unique barriers can lead to psychiatric medication adherence rates as low as 26%.

Statins such as simvastatin do not have additional antidepressive effects in combination with standard escitalopram treatment in patients with comorbid major depressive disorder (MDD) and obesity.

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.

The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.

A multidisciplinary team enhances psychiatric care by empowering community pharmacists to administer long-acting injectable antipsychotics, improving patient adherence and outcomes.

Ambulatory pharmacists innovate care delivery, enhancing patient access and outcomes through home visits and harm reduction clinics for complex health needs.

Never taking a break does more harm than good.

In a session at the 2025 Virtual Conference on Pain and Palliative Care, Isabella Zerfas, PharmD, and Abbey Galligan, PharmD, BCPS, explore effective pain management strategies for opioid use disorder (OUD) and complex persistent opioid dependence.

The treatment could hold significant potential for major depressive disorder

With Oregon, Colorado, and New Mexico legalizing psilocybin-assisted therapy, opportunities for treatment are expanding.